'Hcv rna' presentation slideshows

Liver Disorders

2.58k views • 173 slides

Individualni pristup u lije ? enju bolesnika s kroni ? nim C hepatitisom Smjernice Hrvatske konsenzus konferencije 2009

Individualni pristup u lije ? enju bolesnika s kroni ? nim C hepatitisom Smjernice Hrvatske konsenzus konferencije 2009. Prof.dr.sc. Adriana Vince Referentni Centar za dijagnostiku i lije ? enje virusnih hepatitisa RH Zagreb, 15.5.2009. Rezolucija o virusnom hepatitisu.

749 views • 53 slides

Treatment of Chronic HCV with Direct-Acting Antivirals (DAAs) hcvguidelinesny

Treatment of Chronic HCV with Direct-Acting Antivirals (DAAs) www.hcvguidelinesny.org. Purpose of this Guideline. Increase the number of NYS residents with chronic HCV infection treated for and cured of HCV.

697 views • 51 slides

National Viral Hepatitis Roundtable HCV Baby Boomer Screening and Linkage to Care Program

National Viral Hepatitis Roundtable HCV Baby Boomer Screening and Linkage to Care Program. Conveying the Urgency of Baby Boomer HCV Testing September 16, 2014. How to Talk about Hepatitis C Testing. Camilla S. Graham, MD, MPH Division of Infectious Disease

428 views • 42 slides

501 views • 37 slides

Navigating Hepatitis C: Navigating Hepatitis C:

Navigating Hepatitis C: Navigating Hepatitis C: What Patients Need to Know avigating Hepatitis C: What Patients Need to Know Need to Know. HCV Screening. Bruce Burkett Executive Director HepC Alliance. Who to Screen.

594 views • 36 slides

New drugs for HCV treatment in solid organ transplantation Xavier Forns Liver Unit

457 views • 30 slides

Advantages of New Generation Direct Acting Antivirals (DAAs) Tarik Asselah MD, PhD

437 views • 29 slides

Hepatitis C Genotyping using a Line Probe Assay

444 views • 25 slides

CASE 1

361 views • 20 slides

Source Plasma Labeling

Source Plasma Labeling. Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009. Outline . Source Plasma label regulations Common information on all Source Plasma labels Source Plasma for manufacturing into injectable products

665 views • 13 slides

WINR Study Flat versus Weight-Based Ribavirin Dosing

241 views • 11 slides

323 views • 11 slides

Sofosbuvir + Ribavirin in HCV Genotype 1 NIH SPARE

234 views • 9 slides

Peginterferon alfa-2a versus Interferon alfa-2a

338 views • 7 slides

Peginterferon alfa-2a +/- Ribavirin for Chronic HCV

212 views • 7 slides

I nterferon alfa-2b +/- Ribavirin for 24 or 48 weeks

141 views • 6 slides

Simeprevir with Peginterferon and Ribavirin in GT-4 RESTORE

252 views • 5 slides

GRIFOLS PLASMA: genotype 2 vB19 sample

367 views • 4 slides

ADAP and Hepatitis B Coverage

ADAP and Hepatitis B Coverage. In June 2012, 29 ADAPs covered at least one of the medications for HBV on their formularies . ADAPs filled 325 hepatitis B treatment prescriptions for 314 clients in June 2012. In FY2011, ADAPs filled 3,473 hepatitis B prescriptions.

156 views • 3 slides